A Phase 1, Open Label, Randomized, Crossover Study Evaluating the Relative Bioavailability and Food Effect of a VX-147 Test Tablet Formulation Compared to a Reference Tablet Formulation in Healthy Adult Subjects
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Inaxaplin (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
- 12 Sep 2023 Status changed from recruiting to completed.
- 15 Aug 2023 Status changed from not yet recruiting to recruiting.
- 24 Jul 2023 New trial record